Johnson & Johnson lifts its 2026 outlook, shares trade firmly on NYSE

Johnson & Johnson has raised its 2026 sales and earnings guidance after a strong first quarter, while investors watch the upcoming mid-July earnings on the NYSE as consensus points to steady growth in the healthcare group.

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-24, 07:07.

Johnson & Johnson (US4781601046) raised its 2026 financial outlook after a strong first quarter and continues to attract attention on the New York Stock Exchange, according to several market reports. The healthcare group now guides for higher sales and earnings while analysts track the upcoming mid-July earnings release on Wall Street.

Guidance lifted for 2026

Johnson & Johnson has increased its 2026 reported sales guidance to a range of roughly 100.3 billion to 101.3 billion US dollars and now expects adjusted earnings per share between 11.45 and 11.65 dollars, following a robust first-quarter performance that exceeded earlier expectations, as summarized by a recent International Business Times analysis. The improved outlook reflects stronger-than-anticipated demand in key pharmaceutical and medtech franchises, reinforcing the company’s growth ambitions in the S&P 500 healthcare sector.

According to commentary cited by MarketBeat, Johnson & Johnson has also announced plans to spend more than 1 billion dollars to expand its Vision manufacturing, packaging and distribution operations in Jacksonville, Florida, supporting domestic ACUVUE contact lens production as part of a broader 55 billion dollar US investment framework over several years, which investors see as a sign of ongoing commitment to capacity and innovation in the United States MarketBeat report on J&J.

Consensus and upcoming earnings

For the near term, analysts expect Johnson & Johnson to deliver second-quarter earnings per share of around 2.83 dollars, with revenue growth and margin trends broadly in line with the updated 2026 guidance, according to the earnings preview data referenced in the International Business Times article IBTimes earnings outlook. The second-quarter results are scheduled for mid-July, positioning the stock for another key data point within the S&P 500 healthcare cohort.

On the dividend side, Johnson & Johnson remains a classic income name, with data from Fidelity showing a share price of about 239.50 US dollars and a daily gain of roughly 3.37 percent as of 2026-06-24, 00:59 Eastern time, which corresponds to a market capitalization in the hundreds of billions of dollars and underlines the group’s role as a heavyweight in global healthcare investing Fidelity price and dividend data.

How Johnson & Johnson earns its money

Johnson & Johnson generates most of its revenue from a diversified mix of prescription pharmaceuticals, medtech and consumer health products, with leading brands such as its ACUVUE contact lenses in the Vision business, which are produced and expanded in US facilities like Jacksonville, Florida, and contribute to recurring cash flows alongside its oncology and immunology drug portfolio.

Where the shares trade today

The Johnson & Johnson shares (US4781601046) trade on 2026-06-24, 00:59 Eastern time on the New York Stock Exchange at about 239.50 US dollars.

Key data on the Johnson & Johnson shares

• Company: Johnson & Johnson
• ISIN: US4781601046
• WKN: 853260
• Ticker: JNJ
• Trading venue: NYSE
• Price (as of 2026-06-24, 00:59): 239.50 USD
• Market cap: around 460 billion USD (as of 2026-06-24)
• Sector / industry: Health Care / Pharmaceuticals & Medical Devices
• Index membership: S&P 500, Dow Jones Industrial Average
• Next earnings date: mid-July 2026 (company guidance)

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. All data and estimates are based on publicly available sources believed to be reliable but cannot be guaranteed for accuracy or completeness. Investors should conduct their own research or consult a licensed financial advisor before making investment decisions.